ESMO 2025

News

ESMO: Datroway, Trodelvy lay claim to frontline TNBC therapy

Two TROP2-targeting drugs, Datroway and Trodelvy, have new data suggesting they could become first-line options for triple-negative breast cancer.

News

ESMO: Clear air emerges between Roche SERD and its rivals

Has Roche taken a lead in the oral SERD category of breast cancer therapies with data showing activity in wild-type ESR1 patients?

Oncology

ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs

At ESMO, pharmaphorum spoke with radiopharmaceutical biotech Isotope Technologies Munich SE (ITM) CEO Dr Andrew Cavey.

Oncology

pharmaphorum podcast Episode 211, ESMO25: Boehringer Ingelheim

ESMO25: Patient-centric oncological futures with Boehringer ...

On new oncology data from Boehringer Ingelheim, with Lykke Hinsch Gylvin, chief medical officer, and Itziar Canamasas, head of oncology, at ESMO 2025.

News

Boehringer Ingelheim and Bayer logos with lung sketch in the middle

ESMO: Boehringer, Bayer seek first-line HER2+ NSCLC role

New trial data back the use of Boehringer's new oral HER2 inhibitor Hernexeos in front-line treatment of HER2+ NSCLC, but Bayer is in hot pursuit.

News

ESMO: Grail's data on cancer blood test firms up

Data from a new phase 3 trial of Grail's blood test for multiple cancers show improved efficacy and a lower rate of false alarms than a prior study.

ESMO: Datroway, Trodelvy lay claim to frontline TNBC therapy

ESMO: Clear air emerges between Roche SERD and its rivals

ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs

ESMO25: Patient-centric oncological futures with Boehringer ...

ESMO: Boehringer, Bayer seek first-line HER2+ NSCLC role

ESMO: Grail's data on cancer blood test firms up

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

ESMO 2025

Editor's Picks